Arndt Vogel (@ArndtVogel) “Zolbetuximab plus gemcitabine and nab-paclitaxel in CLDN18.2+ metastatic PDAC: p” — TopicDigg
Arndt Vogel
@ArndtVogel
Clinician-Scientist, ESMO Ambassador, focussed on Liver Cancer & Precision Oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪
加入 February 2013
884 正在关注 9.5K 粉丝
Zolbetuximab plus gemcitabine and nab-paclitaxel in CLDN18.2+ metastatic PDAC: phase II GLEAM study
@ESMO-GI
👉Primary endpoint not met, no OS & PFS benefit
👉Toxicity manageable
🧐Not the right drug, but maybe the right target
显示更多
